Text Size

Study of the Long-Term Effect of Frequent Anti-VEGF Dosing on Retinal Function in Patients With Neovascular AMD

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2007 by Tel-Aviv Sourasky Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT00533689
First received: September 20, 2007
Last updated: NA
Last verified: September 2007
History: No changes posted
  Purpose

THis study aims to determine whether frequent dosing of intravitreal injections of Ranibizumab (Lucentis) or Bevacizumab (Avastin), which act as VEGF inhibitors, has a deleterious effect on the retina, studied by electrophysiologic testing.

This prospective, non-randomized clinical study will include patients assigned to intravitreal injection of Ranibizumab or Bevacizumab due to neovascular AMD. The patients will undergo repeat ophthalmic evaluation and intravitreal injections every 4-6 weeks, as long as will be deemed necessary. Periodic electrophysiologic evaluation including Electroretinogram (ERG), electro-oculogram (EOG) and Visual Evoked Potentials (VEP) tests will be performed every 3 months.


Condition Intervention Phase
Electrophysiology
 Procedure: Electroretinography (ERG), Visual Evoked Potentials (VEP)
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Estimated Enrollment: 2008
Study Start Date: January 2008
Estimated Study Completion Date: January 2010
  Eligibility

Ages Eligible for Study:   50 Years to 90 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Diagnosis of CNV secondary to AMD
  • No other ocular disease
  • No history of kerato-refractive surgery
  • No epilepsy
  • Ability to perform electrophysiologic study

Exclusion Criteria:

  • Pregnancy
  • Minority
  • Epilepsy
  • History of kerato-refractive surgery
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00533689

Contacts
Contact: Michaella Goldstein, MD +972-3-6925773 michgold@netvision.net.il
Contact: Shiri Soudry, MD +972-3-6925773 shirizayit@gmail.com

Locations
Israel
Departent of Ophthalmlogy, Tel Aviv Sourasky Medical Center Not yet recruiting
Tel Aviv, Israel, 64239
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Investigators
Principal Investigator: Michaella Goldstein, MD Tel-Aviv Sourasky Medical Center
Study Director: Anat Loewenstein, MD Tel-Aviv Sourasky Medical Center
Study Chair: Ido Perlman, PhD Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00533689     History of Changes
Other Study ID Numbers: TASMC-07-MG-209-CTIL
Study First Received: September 20, 2007
Last Updated: September 20, 2007
Health Authority: Israel: Ministry of Health

ClinicalTrials.gov processed this record on May 22, 2013